Abstract: Objective To observe the efficacy and safety of tenofovir（TDF） in the treatment of patients with chronic hepatitis B（CHB）. Methods Sixty naive patients with CHB were enrolled in our hospital between January 2015 and December 2016,and were randomly divided into two groups,with 30 patients in each group. 30 patients with CHB were given TDF and the other 30 patients with CHB were given entecavir （ETV） treatment for 96 weeks. Serum alanine aminotransferase （ALT） and HBV DNA levels,as well as virological and biochemical response rates were compared between the two groups. Results Before treatment and at the end of 12 w,24 w,48 w,72 w and 96 w of treatment,serum HBV DNA levels in TDF-treated group were（7.5±0.9） lg IU/mL,（1.7±1.4）lg IU/mL,（1.1±1.0） lg IU/mL,（1.0±0.8） lg IU/mL,（0.7±0.6） lg IU/mL and（0.6±0.5） lg IU/mL,and in ETV-treated group were （6.8±1.5） lg IU/mL,（2.1±1.1） lg IU/mL,（1.8±1.1） lg IU/mL,（1.0±0.7） lgIU/mL,（0.8±0.8） lg IU/mL and （0.9±0.8） lg IU/mL,suggesting that at the first 24 w treatment,serum HBV DNA levels in TDF-treated group were significantly lower than in ETV-treated group （P<0.05）;serum ALT levels in TDF-treated group were （205.8±23.8） U/L,（80.7±8.6） U/L,（49.7±12.5） U/L,（46.2±6.7） U/L,（42.5±6.5） U/L and（41.8±2.4） U/L,and in ETV-treated group were （199.0±25.9） U/L,（99.8±11.0） U/L,（59.3±9.4） U/L,（53.9±8.8） U/L,（44.62±7.4） U/L and （42.7±4.5） U/L,respectively,showing than at the first 24 w,serum ALT levels in TDF-treated group decreased more obviously than in ETV-treated group （P<0.05）;at the end of 12 w,24 w,48 w,72 w and 96 w,the virologic response rates in TDF-treated group were 50.0%,70.0%,73.3%,80.0% and 96.7%,while in ETV-treated group were 23.3%（P<0.05）,56.7%,60.0%,70.0% and 93.3%,respectively;serum ALT normalization rates in TDF-treated group were 63.3%,96.7%,96.7%,100.0% and 100.0%,while in ETV-treated group were 50.0%,86.7%,96.7%,96.7% and 100.0%,showing no significantly different between the two groups （P>0.05）. Conclusion Both TDF and ETV might be the optimal option for treatment of naive patients with CHB at present, showing promising efficacy and good safety,which worth further and long-term investigation.

Key words: Chronic hepatitis B, Tenofovir, Entecavir, Therapy, Response